GBM-LODER for brain cancer
Pipeline
Research
Preclinical
Phase 1
Phase 2
Phase 3
NDA
GBM-LODER for Brain Cancer
Glioblastoma Multiforme (GBM) is the most common and most aggressive malignant primary brain tumor. The GBM solid tumor is relatively diffused, showing extremely aggressive proliferation from a core to other brain tissues. At Silenseed, we are developing a new generation LODER delivery platform (“LODER-nano”) optimized to the specific physiology of this type of brain tumor. Silenseed is exploring the potential of using RNAi-based therapeutics combined with the LODER-nano to yield the optimal combination of high efficacy and low toxicity. Several prospective targets for our RNAi-based drugs currently are in pre-clinical evaluation.